id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-N-3947-0001,FDA,FDA-2026-N-3947,Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comments,Notice,Request for Comments,2026-05-01T04:00:00Z,2026,5,2026-05-01T04:00:00Z,2026-07-01T03:59:59Z,2026-05-09T09:00:22Z,2026-08524,1,0,09000064b92bb6d7